Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:clinicalTrialPhase |
some in clinical trials
|
| gptkbp:compatibleWith |
gptkb:FDA
|
| gptkbp:discoveredIn |
1990s
|
| gptkbp:example |
gptkb:PF-04457845
gptkb:URB597 BIA 10-2474 JZL195 |
| gptkbp:failedTrial |
BIA 10-2474
|
| https://www.w3.org/2000/01/rdf-schema#label |
FAAH inhibitors
|
| gptkbp:mechanismOfAction |
inhibit breakdown of endocannabinoids
|
| gptkbp:relatedTo |
gptkb:cannabinoid_receptors
gptkb:endocannabinoid_system |
| gptkbp:routeOfAdministration |
oral
intraperitoneal |
| gptkbp:sideEffect |
liver toxicity
neurological symptoms |
| gptkbp:target |
gptkb:fatty_acid_amide_hydrolase
|
| gptkbp:usedFor |
pain management
peripheral neuropathy anxiety disorders |
| gptkbp:bfsParent |
gptkb:CB1_receptor_(indirect)
|
| gptkbp:bfsLayer |
6
|